Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Common Equity (2020 - 2026)

Lucid Diagnostics filings provide 6 years of Common Equity readings, the most recent being $10.9 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 102.86% to $10.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.9 million, a 102.86% increase, with the full-year FY2025 number at $10.9 million, up 102.86% from a year prior.
  • Common Equity hit $10.9 million in Q4 2025 for Lucid Diagnostics, down from $25.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $54.7 million in Q4 2021 to a low of -$24.1 million in Q3 2021.
  • Median Common Equity over the past 5 years was $11.4 million (2024), compared with a mean of $12.3 million.
  • Biggest five-year swings in Common Equity: soared 504.93% in 2021 and later tumbled 145.21% in 2025.
  • Lucid Diagnostics' Common Equity stood at $54.7 million in 2021, then crashed by 57.9% to $23.0 million in 2022, then plummeted by 110.03% to -$2.3 million in 2023, then soared by 333.28% to $5.4 million in 2024, then skyrocketed by 102.86% to $10.9 million in 2025.
  • The last three reported values for Common Equity were $10.9 million (Q4 2025), $25.8 million (Q3 2025), and $7.9 million (Q2 2025) per Business Quant data.